Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.76 AUD
Change Today -0.01 / -1.30%
Volume 304.5K
As of 1:10 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

starpharma holdings ltd (SPL) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/19/15 - A$0.85
52 Week Low
12/16/14 - A$0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

starpharma holdings ltd (SPL) Related Businessweek News

No Related Businessweek News Found

starpharma holdings ltd (SPL) Details

Starpharma Holdings Limited researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of VivaGel, a microbicidal agent in Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for prevention of sexual transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel in Phase I clinical trial for breast, prostate, lung, and ovarian tumor; and agrochemicals. Starpharma Holdings Limited was founded in 1996 and is headquartered in Melbourne, Australia.

Founded in 1996

starpharma holdings ltd (SPL) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: A$613.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$231.4K
Vice President of Research
Total Annual Compensation: A$253.7K
Vice President of Business Development
Total Annual Compensation: A$244.4K
Vice President of Development & Regulatory Af...
Total Annual Compensation: A$221.5K
Compensation as of Fiscal Year 2015.

starpharma holdings ltd (SPL) Key Developments

Starpharma Holdings Limited Presents at Virtual Investor Conference, Oct-01-2015 12:15 PM

Starpharma Holdings Limited Presents at Virtual Investor Conference, Oct-01-2015 12:15 PM. Speakers: Jackie Fairley, Chief Executive Officer.

Starpharma Receives EU Marketing Approval for VivaGel BV

Starpharma announced it has received, marketing approval in the European Union (EU) for VivaGel BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms. The approval allows for the marketing of VivaGel BV in the European Economic Area (EEA), which includes the 28 countries of the EU plus the European Free Trade Association (EFTA) countries, providing access to a population of more than 260 million women. In addition, the EU approval will be used as the basis for obtaining what is expected to be relatively rapid regulatory and marketing approvals for VivaGel BV in a number of other countries that formally recognise the EU approval. In clinical trials, VivaGel BV, when used once daily for seven days, demonstrated significant benefits over a placebo in the treatment of BV in women. A key benefit of VivaGel BV in clinical trials was the rapid relief of patients’ symptoms associated with BV, including unpleasant vaginal odour and discharge. In addition, use of VivaGel BV helped to normalise vaginal pH and suppress the bacteria that cause the vaginal microflora imbalance that characterises BV. In formal market research BV sufferers using VivaGel BV reported very high levels of overall satisfaction, comfort and ease of use.

Starpharma Signs Licensing Agreement with AstraZeneca

Starpharma announced the signing of a licensing agreement with AstraZeneca for development and commercialization of compounds directed at a defined family of targets using its DEP drug delivery technology. AstraZeneca will fund all development and commercialization costs under the agreement, including ongoing and future collaborative work conducted with Starpharma. Under the agreement, Starpharma will receive a signature payment of $2 million and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP product of $124 million. Starpharma said its other programs, including its wholly-owned DEP docetaxel product, are not negatively impacted by this arrangement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPL:AU A$0.76 AUD -0.01

SPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPL.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 136.5x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 118.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STARPHARMA HOLDINGS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at